<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01173692</url>
  </required_header>
  <id_info>
    <org_study_id>2010-0096</org_study_id>
    <secondary_id>CA07</secondary_id>
    <secondary_id>NCI-2012-01783</secondary_id>
    <nct_id>NCT01173692</nct_id>
  </id_info>
  <brief_title>Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.</brief_title>
  <official_title>Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if minocycline can reduce the symptoms&#xD;
      reported by patients with oropharynx cancer, nasopharynx cancer, or unknown primary cancer of&#xD;
      head and neck, who receive treatment with radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drug:&#xD;
&#xD;
      Minocycline is an antibiotic and has been shown to interrupt cytokine production, which may&#xD;
      help to reduce multiple symptoms.&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      If you agree to take part in this study, you will be randomly assigned (as in the flip of a&#xD;
      coin) to 1 of 2 groups. Group 1 will take minocycline. Group 2 will take a placebo. A placebo&#xD;
      is a substance that looks like the study drug but has no active ingredients.&#xD;
&#xD;
      Neither you nor the study staff will know if you are receiving the study drug or the placebo.&#xD;
      However, if needed for your safety, the study staff will be able to find out what you are&#xD;
      receiving.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      You will take the study drug/placebo, by mouth, every day for 7 weeks starting at the first&#xD;
      week of radiation therapy. You may take the study drug/placebo with a full glass (8 ounces)&#xD;
      of water. You may take it with or without food. If it causes an upset stomach, you should&#xD;
      take it with food. If you have trouble swallowing the dose of study drug/placebo, you can&#xD;
      open the capsule right before you take them. You should not lie down for at least 30 minutes&#xD;
      after taking the study drug/placebo to prevent possible irritation of the inside of the&#xD;
      esophagus, a known side effect. You will be given pamphlets with more information about how&#xD;
      to take the study drug/placebo.&#xD;
&#xD;
      You will be given a daily diary to write down what time you take the study drug/placebo. You&#xD;
      must bring the diary with you to every study visit for the study doctor and research staff to&#xD;
      review.&#xD;
&#xD;
      You must bring the study drug/placebo container to every study visit.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      Before you start your radiation treatment:&#xD;
&#xD;
        -  You will have blood (about 2 teaspoons) drawn to check your liver function, if this test&#xD;
           has not been done in the last 3 months.&#xD;
&#xD;
        -  If you are able to become pregnant, you will have a urine pregnancy test. The study&#xD;
           staff will give you the pregnancy test kit, and will review and record the results of&#xD;
           the test before you can pick up the study drug from the pharmacy. If you are pregnant,&#xD;
           you will not be given the study drug.&#xD;
&#xD;
        -  You will also complete 5 questionnaires about pain and other symptoms, your alcohol and&#xD;
           tobacco history, your health status, and your quality of life. It should take about 15&#xD;
           minutes to complete all of the questionnaires.&#xD;
&#xD;
      During radiation treatment (approximately Weeks 1- 7 of radiation):&#xD;
&#xD;
      You will complete the symptom questionnaire in the clinic or by telephone 2 times a week. You&#xD;
      will be asked about symptoms you may be experiencing and how they may be interfering with&#xD;
      your normal daily activities. You will complete the symptom questionnaire during one of your&#xD;
      regular clinic visits. If you do not have a clinic visit scheduled around the time that the&#xD;
      questionnaire needs to be completed, a member of the study staff will call you at your home&#xD;
      at a time that is convenient for you. The symptom questionnaire should take about 5 minutes&#xD;
      to complete each time.&#xD;
&#xD;
      At about Week 4 of radiation, you will complete 4 additional questionnaires about pain and&#xD;
      other symptoms, your tobacco use, and a quality of life questionnaire. It should take about 5&#xD;
      minutes to complete all of the questionnaires.&#xD;
&#xD;
      During the last week of radiation (about Week 6-7), you will complete 4 additional&#xD;
      questionnaires about pain and other symptoms, your health status, and your quality of life.&#xD;
      It should take about 10 minutes to complete all of the questionnaires.&#xD;
&#xD;
      Starting after the last week of radiation (about Weeks 7-10), the study staff will call you 2&#xD;
      times each week to check on you. This phone call should last about 5 minutes. If you have had&#xD;
      several side effects from the radiation therapy, this phone call may take longer.&#xD;
&#xD;
      Follow-Up Phone Calls:&#xD;
&#xD;
      During Weeks 11-15, you will complete the pain and other symptoms questionnaire 1 time a week&#xD;
      by phone. A member of the study staff will call you at your home at a time that is convenient&#xD;
      for you. The symptom questionnaire should take about 5 minutes to complete by phone each&#xD;
      time.&#xD;
&#xD;
      End of Study Visit:&#xD;
&#xD;
      Your last study visit will be the same day that you have your last clinic visit with the&#xD;
      radiation doctor (around Weeks 13-15). At this visit, you will complete the pain and other&#xD;
      symptoms questionnaire, your health status and the 2 smoking questionnaires. It should take&#xD;
      about 5 minutes to complete both questionnaires.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will be on study for up to 15 weeks. You will take the study drug/placebo for up to 7&#xD;
      weeks and continue to complete the symptom survey until 15 weeks. You will be taken off study&#xD;
      early if you experience intolerable side effects or the study doctor thinks it is in your&#xD;
      best interest.&#xD;
&#xD;
      This is an investigational study. Minocycline is FDA approved and commercially available for&#xD;
      the treatment of bacterial infection. Using minocycline for the treatment of the symptoms of&#xD;
      radiation treatment for oropharynx cancer, nasopharynx cancer, or unknown primary cancer of&#xD;
      head and neck, is investigational.&#xD;
&#xD;
      Up to 60 patients will take part in this research study. All will be enrolled at MD Anderson&#xD;
      main campus as well as the regional care centers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2010</start_date>
  <completion_date type="Actual">July 7, 2020</completion_date>
  <primary_completion_date type="Actual">July 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined AUC for Selected Patient Symptoms</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>7-week (+/- 5 days) average area under the curve (AUC) for select MD Anderson Symptom Inventory for head and neck cancer (MDASI-HNC) symptoms namely fatigue, pain, sleep disturbance, difficulty swallowing and lack of appetite reported in the symptom survey. Each item is rated on a 11-point scale from 0 (not at all) to 10 (as bad as you can imagine). Higher values represent a worse outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Oropharynx Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice Daily Orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg Twice Daily Orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.</description>
    <arm_group_label>Minocycline</arm_group_label>
    <other_name>Dynacin</other_name>
    <other_name>Minocin</other_name>
    <other_name>Minocin PAC</other_name>
    <other_name>Myrac</other_name>
    <other_name>Solodyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a pathologically proven diagnosis of oropharyngeal cancer,&#xD;
             nasopharyngeal cancer, or unknown primary cancer of head and neck in MDACC receiving&#xD;
             radiation therapy with or without induction chemotherapy.&#xD;
&#xD;
          2. Patients &gt; = 18 years old.&#xD;
&#xD;
          3. Patients with the above cancers, T0, TX, T1 to T3, N any, M0 receiving IMRT (to&#xD;
             unilateral or bilateral neck) at least 64-72 Gy in 6-7 weeks as definitive treatment.&#xD;
&#xD;
          4. Patients must have normal renal function test and no prior renal disease: The&#xD;
             screening cut off for serum creatinine &lt; upper limit of normal.&#xD;
&#xD;
          5. Patients must have normal hepatic function test and no prior liver disease: The&#xD;
             screening results for total bilirubin must be &lt; 1.5 times the upper limit of normal.&#xD;
             The screening results for the following must be &lt; 2 times the upper limit of normal&#xD;
             for patients to be eligible: Alkaline phosphatase (ALP) and Alanine aminotransferase&#xD;
             (ALT). The screening results for Aspartate aminotransferase (AST) must be &lt; 2 times&#xD;
             the upper limit of normal if available.&#xD;
&#xD;
          6. Patients who speak English (due to the novel research and its complexity, we are only&#xD;
             accruing English speaking patients to the protocol).&#xD;
&#xD;
          7. Patients must be willing to discontinue taking dong quai and/or St John's wort.&#xD;
&#xD;
          8. Patients must be willing and able to review, understand, and provide written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients receiving concurrent chemotherapy or concurrent biologic agent.&#xD;
&#xD;
          2. Patients who are taking medications or have conditions that potentially preclude use&#xD;
             of any study medications or interventions as determined by the treating physician.&#xD;
&#xD;
          3. Patients who are enrolled in another symptom management trial or receiving active&#xD;
             treatment under another clinical trial.&#xD;
&#xD;
          4. Bile duct obstruction or cholelithiasis.&#xD;
&#xD;
          5. History of clinically significant cutaneous drug reaction, or a history of clinically&#xD;
             significant hypersensitivity reaction, including multiple allergies or drug reaction.&#xD;
&#xD;
          6. Pre-existing psychosis or bipolar disorder.&#xD;
&#xD;
          7. Hypersensitivity to any tetracyclines.&#xD;
&#xD;
          8. Patients on anticoagulants (ie warfarin/heparin).&#xD;
&#xD;
          9. Patients with INR &gt; 1.5.&#xD;
&#xD;
         10. Patients taking any tetracycline within the last 15 days.&#xD;
&#xD;
         11. Patients that are pregnant.&#xD;
&#xD;
         12. Patients treated with upfront radical surgery at the primary site (other than&#xD;
             diagnostic tonsillectomy or excision).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary B. Gunn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 29, 2010</study_first_submitted>
  <study_first_submitted_qc>July 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2010</study_first_posted>
  <results_first_submitted>July 2, 2021</results_first_submitted>
  <results_first_submitted_qc>August 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2021</results_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oropharynx Cancer</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>XRT</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Minocycline</keyword>
  <keyword>Symptoms</keyword>
  <keyword>Head and Neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT01173692/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: July 22, 2010 to Oct 10, 2013. All recruitment done at the University of Texas MD Anderson Cancer</recruitment_details>
      <pre_assignment_details>47 participants enrolled and assigned to the study drug. 7 participants withdraw after consent or within 2 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Minocycline</title>
          <description>Minocycline 100mg (capsule) two times a day during the entire course of radiation therapy (7 weeks ± 5 days)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo 100mg (capsule) two times a day during the entire course of radiation therapy (7 weeks ± 5 days)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Minocycline</title>
          <description>Minocycline 100mg (capsule) two times a day during the entire course of radiation therapy (7 weeks ± 5 days)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo 100mg (capsule) two times a day during the entire course of radiation therapy (7 weeks ± 5 days)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Combined AUC for Selected Patient Symptoms</title>
        <description>7-week (+/- 5 days) average area under the curve (AUC) for select MD Anderson Symptom Inventory for head and neck cancer (MDASI-HNC) symptoms namely fatigue, pain, sleep disturbance, difficulty swallowing and lack of appetite reported in the symptom survey. Each item is rated on a 11-point scale from 0 (not at all) to 10 (as bad as you can imagine). Higher values represent a worse outcome.</description>
        <time_frame>Up to 7 weeks</time_frame>
        <population>Of 47 randomized patients, 40 (85% were evaluable for the primary efficacy analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100mg (capsule) two times a day during the entire course of radiation therapy (7 weeks ± 5 days)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 100mg (capsule) two times a day during the entire course of radiation therapy (7 weeks ± 5 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Combined AUC for Selected Patient Symptoms</title>
          <description>7-week (+/- 5 days) average area under the curve (AUC) for select MD Anderson Symptom Inventory for head and neck cancer (MDASI-HNC) symptoms namely fatigue, pain, sleep disturbance, difficulty swallowing and lack of appetite reported in the symptom survey. Each item is rated on a 11-point scale from 0 (not at all) to 10 (as bad as you can imagine). Higher values represent a worse outcome.</description>
          <population>Of 47 randomized patients, 40 (85% were evaluable for the primary efficacy analysis)</population>
          <units>score on a scale*week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1"/>
                    <measurement group_id="O2" value="3.7" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of the study medication, up to 30 days after last dose administered.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Minocycline</title>
          <description>Minocycline 100mg (capsule) two times a day during the entire course of radiation therapy (7 weeks ± 5 days)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo 100mg (capsule) two times a day during the entire course of radiation therapy (7 weeks ± 5 days)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brandon Gunn, MD/ Associate Professor, Radiation Oncology Department</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 563-2562</phone>
      <email>gbgunn@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

